N Engl J Med 2021 Apr 22
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Related Questions
The patient is treatment naïve and asymptomatic. She also has disease in the body (bone and liver metastases).
New comment by Medical Oncologist at British Columbia Cancer Agency ( September 22, 2021)
Thank you!
Completely agree with Dr. @Reva K. Basho. The role of intrathecal therapy in HR+HER2- disease does seem to be diminishing, and used only in certain centers for the...
Are there specific patient cohorts in whom you will more preferentially use sacituzumab govitecan?
Can data from ASCENT be applied to patients with C...
New answer by Medical Oncologist at Sarah Cannon Research Institute (November 3, 2021)
The approval of sacituzumab has given us a powerful tool in our bag of options for TNBC. In the ASCENT trial, remember that treatment of physician’s choice (TPC) ch...
Given seemingly improved efficacy in ASCENT patients who had less prior treatment, would you consider use after only one prior agent rather than two? ...
New answer by Medical Oncologist at Sarah Cannon Research Institute (November 3, 2021)
Sacituzumab is approved for patients with metastatic TNBC that have received at least 2 prior lines. However, the FDA specifies only one of these lines needs to be for metasta...
Many of the patients on ASCENT trial were heavily pre-treated and require growth factors. With the day 1,8 treatment cycle, is there a way to minimize...
New comment by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty ( November 25, 2021)
3 to 4 days daily per week growth factors not user friendly. Especially if patients are driving a long distance. Not to mention the constant reminder of cancer and treatment a...
In patients with prior perioperative immunotherapy with early relapse, would re-introduction of immunotherapy be reasonable with high TMB?
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (June 22, 2022)
Atezolizumab was granted accelerated approval by FDA in March 2019 based on data from the phase 3 IMpassion130 trial which demonstrated a statistically significant benefit to ...